- Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain
- Walter Reed National Military Medical Center Acquires a Brainsway Deep TMS System to Enhance its Treatment of Depression
- Noblegen Announces the Opening of Its Second Round of Financing: Peterborough-based biotechnology startup targeting up to $50 million in equity financing
- Burcon Announces Fiscal 2017 Results and Reviews Operations
- Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
- The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement
- Yield10 Bioscience CEO Dr. Oliver Peoples to Present at BIO 2017
- Adverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical Officer
- Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
- ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye
